Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

8.260 +0.150 (+1.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mind Medicine Mindmed Inc

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
Via Benzinga
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024
MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
3 Psychedelic Stocks to Ride to the Moon and Beyond
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. 
Via InvestorPlace
Exposures Product Safety
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
Via Talk Markets
Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M
The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain. 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
Discover top strong buy penny stocks, poised for impressive gains as market indices climb, offering unique opportunities. 
Via InvestorPlace
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
Via Talk Markets
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
Exposures Product Safety
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).... 
Via Benzinga
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
The Time Traveler’s Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
These long-term stocks to buy may seem speculative today, but so did Nvidia in 2024 -- and they may match the chipmaker's returns by 2034. 
Via InvestorPlace
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
Regarding Hertz, Jim Cramer said, "I don't want you to sell, and I don't want you to double down. Let's just see if it can't go higher." 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
Some of the top Russell 2000 stocks to buy are those that few investors pay attention to but offer great potential nonetheless. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.